Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LSKL, Inhibitor of Thrombospondin TSP-1 acetate 是 TGF-β 的激活剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 415 | 现货 | ||
2 mg | ¥ 597 | 现货 | ||
5 mg | ¥ 837 | 现货 | ||
10 mg | ¥ 1,310 | 现货 | ||
25 mg | ¥ 2,390 | 现货 | ||
50 mg | ¥ 3,680 | 现货 | ||
100 mg | ¥ 5,290 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,230 | 现货 |
产品描述 | LSKL, Inhibitor of Thrombospondin TSP-1 acetate is activation of TGF-β . |
体内活性 | Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy |
动物实验 | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
别名 | LSKL, Inhibitor of Thrombospondin TSP-1 |
分子量 | 686.64 |
分子式 | C25H44F6N6O9 |
CAS No. | T7676 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27.5 mg/mL (40.05 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.4564 mL | 7.2818 mL | 14.5637 mL | 36.4092 mL |
5 mM | 0.2913 mL | 1.4564 mL | 2.9127 mL | 7.2818 mL | |
10 mM | 0.1456 mL | 0.7282 mL | 1.4564 mL | 3.6409 mL | |
20 mM | 0.0728 mL | 0.3641 mL | 0.7282 mL | 1.8205 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
LSKL, Inhibitor of Thrombospondin TSP-1 acetate T7676 Stem Cells TGF-beta/Smad LSKL, Inhibitor of Thrombospondin TSP1 acetate LSKL, Inhibitor of Thrombospondin TSP 1 acetate LSKL, Inhibitor of Thrombospondin TSP-1 Acetate LSKL, Inhibitor of Thrombospondin TSP-1 Inhibitor inhibitor inhibit